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Abstract
Background: Leukemia inhibitory factor (LIF) and interleukin-6 (IL-6) are members of the family of the glycoprotein 130
(gp130)-type cytokines. These cytokines share gp130 as a common signal transducer, which explains why they show some
functional redundancy. Recently, it was demonstrated that IL-6 promotes fetal lung branching. Additionally, LIF has been
implicated in developmental processes of some branching organs. Thus, in this study LIF expression pattern and its effects
on fetal rat lung morphogenesis were assessed.
Methodology/Principal Findings: LIF and its subunit receptor LIFRa expression levels were evaluated by immunohisto-
chemistry and western blot in fetal rat lungs of different gestational ages, ranging from 13.5 to 21.5 days post-conception.
Throughout all gestational ages studied, LIF was constitutively expressed in pulmonary epithelium, whereas LIFRa was first
mainly expressed in the mesenchyme, but after pseudoglandular stage it was also observed in epithelial cells. These results
point to a LIF epithelium-mesenchyme cross-talk, which is known to be important for lung branching process. Regarding
functional studies, fetal lung explants were cultured with increasing doses of LIF or LIF neutralizing antibodies during 4
days. MAPK, AKT, and STAT3 phosphorylation in the treated lung explants was analyzed. LIF supplementation significantly
inhibited lung growth in spite of an increase in p44/42 phosphorylation. On the other hand, LIF inhibition significantly
stimulated lung growth via p38 and Akt pathways.
Conclusions/Significance: The present study describes that LIF and its subunit receptor LIFRa are constitu-
tively expressed during fetal lung development and that they have an inhibitory physiological role on fetal lung
branching.
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Introduction
Fetal lung development is a complex process, involving several
effectors such as growth factors, extracellular matrix interactions,
hormones and as, recently described inflammatory mediators [1–
3]. In fact, it was already demonstrated that interleukin-6 (IL-6)
promotes fetal lung maturation [4–6] and also that IL-6 is
constitutively expressed in pulmonary primitive epithelium and
enhances fetal lung branching [3].
IL-6 is one of the members of the family of the glycoprotein 130
(gp130)-type cytokines. This family comprises IL-6, leukemia
inhibitory factor (LIF), IL-11, oncostatin M, ciliary neurotrophic
factor (CNTF), cardiotropin-1 (CT-1) and cardiotrophin-like
cytokine. These cytokines share the membrane glycoprotein
gp130 as a common signal transducer which explains the fact
that these show some functional redundancy even though they also
exhibit specific biological activities [7,8].
LIF is a pleiotropic cytokine, that exists in both soluble and
matrix-bound forms, and that binds to a heterodimer LIF receptor
alpha subunit (LIFRa)/gp130. Signal transduction involves the
activation of Janus kinase (JAK) and the subsequent recruitment of
signal transducers and activators of transcription (STAT) proteins,
mainly STAT3. Alternatively, LIF can also initiate cell signaling
via the mitogen-activated protein kinase (MAPK) cascade [7–10].
Moreover, LIF displays several biological activities ranging from
the classic differentiation of myeloid leukemic cells into macro-
phage lineage to effects on proliferation of primordial germ cells,
maintenance of embryonic stem cell pluripotentiality, endometrial
decidualization, blastocyst implantation, neural development,
bone cell metabolism, adipocyte lipid and energy homeostasis,
muscle satellite cell proliferation, heart hypertrophy, inhibition of
retinal vascularization and inflammation [9–13]. Furthermore,
several studies have emphasized the importance of LIF signaling in
several processes of branching organs. For instance, this cytokine
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inhibits fetal nephrons formation [14–16], induces mammary
gland involution [17], decreases thyroid tumors growth [18,19]
and increases pancreatic regeneration [20]. It was already
described that LIF, together with insulin-like growth factor I
(IGF-I), regulates lung maturation. In fact, absence of LIF in
addition to IGF-I null mutant mice aggravates pulmonary
immaturity. Indeed, LIF/IGF-I double deficient embryos present
lung hypoplasia and defective differentiation of the alveolar
epithelium and vasculogenesis [21].
Regardless of several evidences in literature that point towards a
possible involvement of LIF during fetal lung development, LIF
expression pattern as well as its effects during lung morphogenesis
are largely unknown. Despite LIF/IGF-I double deficient mice
lung phenotype, LIF knockout mice have no significant abnormal
lung features [21,22]. However, in the current study, it was
demonstrated that LIF and LIFRa were constitutively expressed
during fetal lung development and that in vitro LIF supplemen-
tation significantly inhibited lung growth, likely through p44/42
pathway.
Results
LIF and LIFRa expression pattern during fetal lung
development
The immunohistochemistry (IHC) and western blot studies
revealed that LIF and LIFRa protein were expressed throughout
all studied gestational ages in fetal lung (Figure 1 and 2). LIF was
mainly expressed in bronchiolar and also in alveolar epithelium
from 13.5 days post-conception (dpc) until term. At 19.5 and 21.5
dpc, mesenchymal tissue also displayed scattered LIF positive cells
(Figure 1A and 1B). These LIF expression results prompted us to
perform a western blot analysis in order to quantify the relative
expression of LIF levels during normal lung development. LIF
expression levels were minimal at 13.5 dpc, increased slightly
throughout gestation and reached its maximum at the end of
gestation (21.5 dpc) (Figure 1C and 1D).
Regarding LIFRa, early in gestation, protein expression was
restricted to the mesenchyme (Figure 2A and 2B). Throughout
fetal lung development, namely from 17.5 dpc onwards, LIFRa
mesenchymal expression decreased and epithelial expression was
observed until term (Figure 2A and 2B). LIFRa expression levels
remained constant during fetal lung development (Figure 2C and
2D).
Role of LIF in fetal lung development
In order to evaluate the role of LIF on lung morphogenesis, fetal
lung explants were treated daily with increasing concentrations of
recombinant LIF. In Figure 3A, representative examples of fetal
lung explants treated with increasing LIF concentrations, after 4
days in culture, are illustrated. LIF appears to have a dose-effect
inhibitory action on lung explants growth. In fact, a decrease in
the total number of peripheral airway buds (Figure 3B), epithelial
perimeter (Figure 3C), area (Figure 3D) and external perimeter
(Figure 3E) of lung explants was observed in all concentrations
Figure 1. LIF expression pattern during fetal lung development (from 13.5 until 21.5 dpc). (A) IHC studies revealed that LIF expression
was localized to airway epithelium. Original magnification: Upper panel –6100; Bottom panel –6200. (B) IHC negative controls: Left – omission of
the primary antibody; Center – non-immune goat IgG isotype control; Right – simultaneous omission of the primary and secondary antibodies. In all
negative controls immunoreactive LIF staining was not observed. (C) Western blot analysis of LIF throughout gestation (45 kDa). Control loading was
performed using b-tubulin (55 kDa). (D) Relative LIF protein levels expressed in arbitrary units normalized for b-tubulin. p,0.05: *vs. 13.5 dpc, 1 vs.
15.5 dpc, { vs. 17.5 dpc, ¥ vs. 19.5 dpc.
doi:10.1371/journal.pone.0030517.g001
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tested, this effect is most significant in the highest LIF
concentrations studied, 20 and 40 ng/mL.
In Figure 4 it is shown the morphometric analysis of lung
explants treated with control IgG, anti-LIF IgG antibodies or
FGF-10. LIF inhibition significantly stimulated lung branching
(Figure 4B) and epithelial perimeter (Figure 4C) in a similar way as
FGF-10. No differences were observed on lung explant area
(Figure 4D) or external perimeter (Figure 4E).
Pooled samples of lung explants (n = 15) treated with LIF at
40 ng/mL (selected due to its maximal effect on inhibition of
explants growth) were evaluated for modulation of MAPK, Akt
and STAT3 pathways (Figure 5). Lung growth inhibition induced
by LIF significantly stimulated p44/42 phosphorylation (Figure 5).
On the other hand, the increase on lung branching induced by
blocking LIF action significantly stimulated p38 and Akt
phosphorylation (Figure 6).
Discussion
This study demonstrated that LIF was constitutively expressed
in pulmonary epithelium, whereas its subunit receptor, LIFRa,
was expressed in the mesenchyme until the pseudoglandular stage
and in epithelial cells, at later stages. Moreover, LIF supplemen-
tation significantly inhibited lung growth most likely through p44/
42 pathway. On the other hand, LIF inhibition significantly
increased lung branching and stimulated p38 and Akt phosphor-
ylation.
LIF is a multifunctional glycoprotein cytokine that regulates
many cellular responses such as proliferation, differentiation and
survival in different cellular types [8–13]. Regarding the lung,
several studies have investigated LIF’s role in the pathophysiology
of different lung diseases, such as acute respiratory distress
syndrome [23], asthma [24], chronic airway inflammation [25]
and inflammation induced by tobacco [23]. In fact, LIF is well
known to induce the synthesis and activation of phospholipase A2
in bronchial epithelial cells [12] and it has protective effects in the
setting of hyperoxic lung injury [26]. Concerning LIF’s putative
role during prenatal lung period, all previous studies had focused
mainly in maturation processes.
In the current study, it was demonstrated that LIF was
expressed in primitive lung epithelium, since early stages of lung
development (13.5 dpc), a moment in which predominantly occurs
growth phenomena. LIF expression in bronchiolar and also in
alveolar epithelium is in agreement with previous findings
documented in adult human lung [25,27,28]. In adults, epithelial
expression was also observed in other branching organs such as
mammary gland [29] and pancreas [20]. During murine fetal
development, LIF expression was already described in the ureteric
bud [15], skin, skeletal muscle, heart, brain, liver and gut [30,31]
supporting a role for this cytokine in the normal development of
Figure 2. LIFRa expression pattern during fetal lung development (from 13.5 until 21.5 dpc). (A) IHC studies revealed that LIFRa was first
mainly expressed in the mesenchyme, but after pseudoglandular stage it was also observed in epithelial cells throughout gestation. Original
magnification: Upper panel –6100; Bottom panel –6200. (B) IHC negative controls: Left – omission of the primary antibody; Center – non-immune
goat IgG isotype control; Right – simultaneous omission of the primary and secondary antibodies. In all negative controls immunoreactive LIFRa
staining was not observed. (C) Western blot analysis of LIFRa throughout the gestation (190 kDa). Control loading was performed using b-tubulin
(55 kDa). (D) Relative LIFRa protein levels expressed in arbitrary units normalized for b-tubulin. No significant difference was observed between
gestational ages.
doi:10.1371/journal.pone.0030517.g002
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several organ systems. Moreover, LIF expression was observed in
all studied gestational ages and its expression levels increased by
the end of the gestation, which is in accordance with the literature
[31].
Regarding LIFRa, it was expressed in constant levels through-
out gestation: first mainly in lung mesenchyme, and after
pseudoglandular stage it was predominantly observed in the
epithelium until term. LIFRa is known to be expressed in
numerous human lung structural cell types, namely fibroblasts,
bronchial smooth muscle cells and airway epithelial cells
[25,27,28]. Interestingly, during fetal kidney morphogenesis,
LIFRa was first detected in metanephric mesenchyme and later
in newly formed tubules [15]. It is necessary to stress that the
occurrence of epithelial LIF and mesenchymal LIFRa expression,
since early stages of lung development and until the end of
pseudoglandular stage, points to a LIF epithelium-mesenchyme
interaction during this stage of lung development, which is mainly
characterized by successive branching phenomena. It is well
described that lung development occurs through specific cross-talk
interactions between epithelium and mesenchyme [1]. Therefore,
LIF and LIFRa interaction might possibly be a new player on lung
branching mechanisms. Nonetheless, the highest LIF expression
was observed at the end of the gestation which also suggests a
physiological role for LIF in lung maturation, as already
demonstrated in literature [21,22].
In order to evaluate LIF’s role in lung branching morphogen-
esis, fetal lung explants were cultured with increasing doses of LIF
or LIF neutralizing antibodies. LIF supplementation inhibited
lung growth, whereas LIF blockage stimulated lung branching.
Interestingly, the blockage of LIF activity increased the number of
peripheral airways buds and epithelial perimeter in a similar way
as FGF-10, a classical and very important lung growth factor that
Figure 3. LIF supplementation studies in a fetal lung explant culture system. (A) Representative examples of fetal lung explants treated
daily with increasing concentrations of recombinant LIF, after 4 days in culture. Original magnification625. (B) Number of total airway buds; (C)
Epithelial perimeter; (D) Area; (E) External perimeter of lung explants treated with LIF. LIF significantly inhibited lung growth. Results are expressed as
ratio of day 4 (D4) and day 0 (D0) of culture (D4/D0 ratio). p,0.05:
* vs. LIF at 0 ng/mL (control), 1 vs. LIF at 0.4 ng/mL, ¥ vs. LIF at 4 ng/mL.
doi:10.1371/journal.pone.0030517.g003
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is known to increase lung branching [32,33]. LIF inhibitory effect
had already been described in fetal kidney development [16] and
in the proliferation of human normal and malign breast epithelial
cells [34] which, like the lung, develop by branching events.
Moreover, LIF inhibitory effect was also described on other cell
types such as embryonic stem cells [35], bone [36], endothelial
[11] and neuronal cells lines [37]. However, LIF stimulates duct
cell proliferation in adult pancreas [18]. Interestingly, this LIF
inhibitory effect on fetal lung branching opposes the stimulatory
effect described for IL-6 [3], also a member of family of the gp130-
type cytokines.
Although this in vitro study clearly suggests a physiological role
for LIF on lung branching, LIF knockout mice do not seem to
have abnormal lung features when compared to normal littermates
[21,22]. Indeed, LIF knockout mice are born normal and they
only exhibit defective blastocyst implantation, postnatal growth
retardation and hematopoiesis defects [22,38,39]. The absence of
significant lung development abnormalities in LIF knockout mice
does not mean a minor role for LIF during lung morphogenesis in
vivo. In fact, as demonstrated for several phenomena, mice lacking
individual members of gp130-type cytokines displayed milder
phenotype than expected, which is most likely due to the similarity
and redundancy of downstream events induced by gp130-
dependent cytokines [38]. On the other hand, LIFRa deletion
causes perinatal death with multiple defects [22,38,40–42].
However, it is necessary to stress that this receptor subunit is a
part of the receptor complexes for LIF, CNTF and CT-1 [8].
Moreover, it is necessary to stress that it is recognized that the
knockout approach also bears intrinsic problems, since the ensuing
phenotype may consist of compensatory events during develop-
ment and later life [43]. In opposition to LIF-deficient lungs, the
additional absence of LIF in the IGF-I-null background of mutant
mice aggravates the prenatal pulmonary immature phenotype and
these mice die due to respiratory failure [21,22]. These results
point to a possible LIF role on lung maturation, but only involving
also IGF-I. Furthermore, lung development is a complex process
involving two different cellular phenomena, maturation and
growth [1], and in the context of present work LIF’s involvement
was studied with regard to the growth phenomena.
In different cells and tissues, LIF signaling is mediated mainly by
JAK/STAT3, p44/42 kinase and PI3K/Akt pathways [7–10,17].
Interestingly, many of the effectors that modulate fetal lung
Figure 4. LIF neutralizing studies in a fetal lung explant culture system. (A) Representative examples of lung explants treated daily with
normal IgG (control; 1 mg/mL), anti-LIF IgG (1 mg/mL) or FGF-10 (500 ng/mL), after 4 days in culture. Original magnification625. (B) Number of total
airway buds; (C) Epithelial perimeter; (D) Area; (E) External perimeter of treated lung explants. Inhibition of LIF action significantly stimulated lung
branching in a similar way than FGF-10. Results are expressed as D4/D0 ratio. p,0.05:
* vs. control IgG.
doi:10.1371/journal.pone.0030517.g004
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branching morphogenesis seem to activate signaling pathways that
converge into the MAPK and PI3K/Akt cascades [44]. Thus,
MAPK, PI3K/Akt and STAT3 pathway modulation by LIF and
anti-LIF in fetal lung development was investigated. The
inhibition of lung growth induced by LIF significantly stimulated
p44/42 phosphorylation and did not significantly change p38,
JNK, Akt or STAT3 pathways. In contrast to these results, in lung
development, the p44/42 pathway has been involved in
stimulation of branching morphogenesis. Indeed, Kling et al
demonstrated that p44/42 inhibition reduces branching morpho-
genesis and causes mesenchymal cell apoptosis in fetal rat lungs
[44]. According to the literature, it is not the first association
between LIF, p44/42 pathway and growth inhibition/arrest. In
fact, in human medullary thyroid cancer cells, it was demonstrated
that p44/42 pathway induces autocrine-paracrine growth inhibi-
tion via LIF [19]. Moreover, the absence of LIF in the IGF-1 null
mice, which induces changes on pulmonary maturation and
vasculogenesis, also induces activation of p44/42 [21]. Further-
more, the LIF action mediated by p44/42 was already
demonstrated in earlier mammary gland development [17] and
myoblasts [45]. Thus, considering that lung explants were
incubated during 4 days, p44/42 stimulation might not be the
Figure 5. Analysis of intracellular signaling pathways that mediates LIF actions on lung growth. (A) Western blot analysis of p38, p44/42,
JNK1/2, Akt and STAT3, and to diphosphorylated forms of p38 (dp-p38), p44/42 (dp-p44/42), SAPK/JNK (dp-JNK1/2), Akt (dp-Akt) and STAT3 (dp-
STAT3) in control lung explants (C) and treated with LIF at 40 ng/mL (LIF). Control loading was performed using b-tubulin (55 kDa). p38 corresponds
to 38 kDa. p44/42 correspond to 44 and 42 kDa, respectively. JNK1 and 2 correspond to 46 and 54 kDa, respectively. Akt corresponds to 60 kDa.
STAT3 corresponds to two bands, 79 and 86 kDa. (B) Semi-quantitative analysis of expression of phosphorylated forms of these intracellular signaling
pathways. Results are presented as arbitrary units normalized for b-tubulin. p,0.05: * vs. control.
doi:10.1371/journal.pone.0030517.g005
LIF and Fetal Lung Development
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30517
direct pathway that mediates LIF action, but the result of
crosstalks of other non-canonical intracellular pathway. Regarding
anti-LIF treatment, the increase on lung branching observed was
mediated by stimulation of p38 and Akt phosphorylation. PI3K/
Akt pathway is a classical stimulator of lung branching [44,46].
Moreover, p38 was already demonstrated as mediator of lung
branching [3,47]. Interestingly, it was demonstrated that IL-6,
another a gp130-type cytokines, also enhances lung branching via
p38 phosphorylation [3].
In this study, it was demonstrated that LIF inhibits lung
branching, in opposition to IL-6 (another cytokine of the gp130
family). Although cytokines of the gp130 family share a common
signal transducer, these findings suggest specific biological
activities for each cytokine on lung development. In fact, specific
characteristics are emerging for each member of this family,
brought about mainly through restricted temporal and spatial
release, differential expression of cell surface receptors, and
different signaling patterns between gp130 homodimers and
heterodimers [25]. Interestingly, LIF receptor is a gp130
heterodimer, whereas IL-6 receptor is a gp130 homodimer. Thus,
this raises the hypothesis that the effect, on lung development, of
cytokine signaling through gp130 heterodimers might be different
and even opposite to gp130 homodimers. Although this hypothesis
needs to be verified, this specificity can possibly represent a
Figure 6. Analysis of intracellular signaling pathways that mediates anti-LIF actions on lung branching. (A) Western blot analysis of p38,
p44/42, JNK1/2, Akt and STAT3, and to diphosphorylated forms of p38 (dp-p38), p44/42 (dp-p44/42), SAPK/JNK (dp-JNK1/2), Akt (dp-Akt) and STAT3
(dp-STAT3) in control IgG lung explants (IgG) and treated with anti-LIF IgG (Anti-LIF). Control loading was performed using b-tubulin (55 kDa). (B)
Semi-quantitative analysis of expression of phosphorylated forms of these intracellular signaling pathways. Results are presented as arbitrary units
normalized for b-tubulin. p,0.05: * vs. IgG.
doi:10.1371/journal.pone.0030517.g006
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regulatory mechanism of lung morphogenesis, intrinsic to this
family of cytokines, in order to achieve the correct lung growth.
In conclusion, LIF and LIFRa expression during fetal lung
development as well as the in vitro studies presented in this work
suggest an inhibitory physiological role for endogenous LIF,
mediated by epithelial-mesenchymal interactions, on pulmonary
branching mechanisms.
Materials and Methods
This study was carried out in strict accordance with the
recommendations in the ‘Guide for the Care and Use of
Laboratory Animals’, published by the US National Institutes of
Health (NIH Publication No.85-23, revised 1996). Animal
experiments were also performed according to the Portuguese
law for animal welfare and the protocol was approved by the
Committee on the Ethics of Animal Experiments of the Life and
Health Sciences Research Institute of the University of Minho
(DGV 022162 - 520/000/000/2006). Moreover, all efforts were
made to minimize animal suffering.
Animal model and experimental design
Sprague-Dawley female rats (225 g; Charles-River, Spain) were
maintained in appropriate cages under temperature-controlled
room (22–23uC) on a 12 hours light: 12 hours dark cycle, and fed
with commercial solid food. The rats were mated and checked
daily for vaginal plug. The day of plugging was defined as
gestational day 0.5 for time dating purposes. Fetuses were removed
by caesarean section at 13.5, 15.5, 17.5, 19.5 and 21.5 dpc (days
post-conception) and sacrificed by decapitation. Lungs were
dissected and processed for IHC and western blot analysis. To
perform fetal lung explant cultures fetuses were harvested at 13.5
dpc and their lungs dissected.
IHC
LIF and LIFRa immunostainings were performed on formalin-
fixed and paraffin-embedded lungs of different gestational ages
(13.5–21.5dpc). Sections (5 mm) were placed on SuperFrostHPlus
slides (Menzel-Glaser, Germany). LIF antibody (sc-1336; Santa
Cruz Biotechnology Inc., USA) was used in a 1:50 dilution and
LIFRa antibody (sc-659; Santa Cruz Biotechnology Inc.) in a 1:50
dilution. After dewaxing in xylene and rehydration in ethanol, the
samples were incubated in 3% hydrogen peroxide in methanol to
quench endogenous peroxidase. Antigen retrieval was achieved by
boiling in 10 mM citrate buffer followed by cool down at room
temperature. Samples were blocked with 5% BSA (Roche,
Germany). Incubation of the primary antibody occurred at 4uC
overnight. Negative control reactions included omission of the
primary antibody, the simultaneous omission of the primary and
secondary antibodies, and a non-immune goat IgG isotype control
diluted to a matching concentration as the primary antibody,
instead of the primary antibody. Incubation with the goat
ImmunoCruzTM Staining System (sc-2053; Santa Cruz Biotech-
nology Inc.) or with the UltraVision detection system anti-
polyvalent horseradish peroxidase (Lab Vision Corporation,
USA) was carried according to manufacturer’s instructions (for
LIF and LIFR immunostainings, respectively). To visualize the
peroxidase activities in sections, diaminobenzidine tetrahy-
drochloride (Dako, Denmark) was used. Sections were counter-
stained with hematoxyline. The slides were observed and
photographed with Olympus BX61 microscope (Olympus, Japan).
The pictures presented are representative of 6 animals (n = 6) and
12 samples for each gestational age, and three independent
experiments were performed.
Western blot analysis
Different pooled lung samples for each gestational age (13.5–
21.5 dpc) and cultured lung explants were processed for western
blot analysis. Proteins were obtained according to Kling et al [44].
Ten or twenty five mg of protein were loaded onto 10% or 7.5%
acrylamide minigels (respectively), electrophoresed at 100 V at
room temperature and then transferred to nitrocellulose mem-
branes (HybondTM -C Extra, GE Healthcare Life Sciences, UK).
Blots were probed with LIF and LIFRa polyclonal antibodies
(Santa Cruz Biotechnology Inc.) according to manufacturer’s
instructions (1:250 and 1:500, respectively). For loading control,
blots were probed with b-tubulin MAb (1:200000, Abcam, UK).
Afterwards blots were incubated with a secondary horseradish
peroxidase conjugate (Santa Cruz Biotechnology Inc.), developed
with Super SignalHWest Femto Substrate (Pierce Biotechnology,
USA) and the chemiluminescent signal was captured using the
Chemidoc XRS (Bio-Rad, USA). Quantitative analysis was
performed with Quantity One 4.6.5 1-D Analysis Software
(Bio-Rad). Three independent experiments were performed
(n = 3).
Fetal lung explant cultures
Harvesting and dissection of 13.5 dpc lungs was made in DPBS
(Lonza, Switzerland) under a dissection microscope (Leica
MZFLIII, Switzerland). The lungs were transferred to Nucleopore
membranes with an 8 mm pore size (Whatman, USA) and
incubated in a 24-well culture plates (Nunc, Denmark). The
membranes were pre-soaked in DMEM (Invitrogen, UK) for
1 hour before the explants were placed on them. Floating cultures
of the explants were incubated in 200 ml of 50% DMEM, 50%
nutrient mixture F-12 (Gibco, USA) supplemented with 100 mg/
ml streptomycin, 100 units/ml penicillin (Gibco), 0.25 mg/mL
ascorbic acid (Sigma-Aldrich, USA) and 10% FCS (Gibco). The
fetal lung explants were incubated in a 5% CO2 incubator at 37uC
for 96 hours, and the medium was replaced every 48 hours. The
branching morphogenesis was monitored daily by photographing
the explants. At day 0 (D0: 0 hours) and day 4 (D4: 96 hours) of
culture, the total number of peripheral airway buds (branching) in
all lung explants was determined, whereas the explants area,
epithelial perimeter and external perimeter were measured using
AxionVision Rel. 4.3 (Carl Zeiss, Germany). These results were
expressed as D4/D0 ratio.
LIF supplementation studies
Twelve lung explants were used as control (0 ng/mL).
Additionally, recombinant LIF (Sigma-Aldrich) was daily added
to lung explants in order to achieve a final concentration of 0.4, 4,
20 and 40 ng/mL (0.4 n = 15; 4 n = 12; 20 n = 12; 40 n = 15).
After 4 days in culture, control and LIF treated lung explants (at
40 ng/mL) were processed for western blot analysis of non-
phosphorylated and phosphorylated forms of p38, p44/42, JNK,
Akt and STAT3 (Cell Signaling Technology Inc., USA) according
to the method described above. Four independent experiments
were performed (n = 4).
LIF neutralizing studies
Lung explants were treated daily with IgG anti-LIF neutralizing
antibody (n = 12) at concentration of 1.0 mg/mL (R&D Systems,
USA). Non-specific effects were evaluated by daily addition of
identical concentration of normal IgG control antibody (n = 9;
R&D Systems). Moreover, lung explants were also treated with
FGF-10 that was added daily to the culture medium at a
concentration of 500 ng/mL (n = 9; R&D Systems).
LIF and Fetal Lung Development
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After 4 days in culture, normal IgG and anti-LIF IgG treated
lung explants were processed for western blot analysis of the
intracellular signaling pathways, as described above (n = 4).
Statistical Analysis
All quantitative data are presented as mean 6 SEM. Statistical
analysis was performed using the statistical software SigmaStat
(version 3.5; Systat Software Inc., USA). For LIF and LIFRa
expression levels evaluation and supplementation studies one-way
ANOVA was used. For LIF neutralizing studies and intracellular
signaling pathways analysis t-test analysis was used. The Student-
Newman-Keuls test was used for post-test analysis. Statistical
significance was set at p,0.05.
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